Patents by Inventor Jesse Jerome Smith

Jesse Jerome Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4?) gene expression
    Patent number: 11987791
    Abstract: The present invention provides agents and compositions for modulating expression (e.g., enhanced or reduced expression) of a hepatocyte nuclear factor 4 alpha (HNF4?) gene by targeting an HNF4? expression control region and methods of use thereof for treating an HNF4? associated disorder, e.g., cirrhosis.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: May 21, 2024
    Assignee: Omega Therapeutics, Inc.
    Inventors: Jesse Jerome Smith, Jodi Michelle Kennedy, Jeremiah D. Farelli, Kendrick Alan Goss, Adam Walter Scheidegger, Yoseph Kassa, Christian Wessel Cobaugh, Timsi Rao
  • OLIGONUCLEOTIDES USEFUL FOR MODULATION OF SPLICING
    Publication number: 20240018522
    Abstract: Described herein are oligonucleotides (e.g., single-stranded oligonucleotides) and compositions thereof for targeting a mutation in the spliceosome, such as the U 1 small nuclear RNA (snRNA), as well as related methods of use.
    Type: Application
    Filed: October 26, 2021
    Publication date: January 18, 2024
    Inventors: Jesse Jerome Smith, Duncan Brown, Michael W. Seiler, Peter Smith, Anant A. Agrawal
  • COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF MULTIPLE GENES
    Publication number: 20230374549
    Abstract: The present disclosure relates to site-specific disrupting agents for modulating, e.g., decreasing, expression of a target plurality of genes in a cell. In some embodiments, the target plurality of genes comprises pro-inflammatory genes, e.g., CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, and IL-8. In some embodiments, the method comprises using a first site-specific disrupting agent that targets a first anchor sequence and a second site-specific disrupting agents that disrupts a second anchor sequence.
    Type: Application
    Filed: September 29, 2021
    Publication date: November 23, 2023
    Inventors: Lauren Marie BEECH, Jesse Jerome SMITH, Rahul KARNIK, Kendrick Alan GOSS, Adam Walter SCHEIDEGGER, Jodi Michelle KENNEDY, Jeremiah Dale FARELLI, Houda BELAGHZAL, Laura Anh NGUYEN, Charles W. O'DONNELL
  • COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4alpha) GENE EXPRESSION
    Publication number: 20220348908
    Abstract: The present invention provides agents and compositions for modulating expression (e.g., enhanced or reduced expression) of a hepatocyte nuclear factor 4 alpha (HNF4a) gene by targeting an HNF4? expression control region and methods of use thereof for treating an HNF4? associated disorder, e.g., cirrhosis.
    Type: Application
    Filed: September 23, 2020
    Publication date: November 3, 2022
    Inventors: Jesse Jerome Smith, Jodi Michelle Kennedy, Jeremiah D. Farelli, Kendrick Alan Goss, Adam Walter Scheidegger, Yoseph Kassa, Christian Wessel Cobaugh, Timsi Rao
  • METHODS AND COMPOSITIONS FOR MODULATING FRATAXIN EXPRESSION AND TREATING FRIEDRICH'S ATAXIA
    Publication number: 20220348893
    Abstract: The present disclosure relates generally to methods and compositions for modulating frataxin (FXN) expression, e.g., to treat Friedreich ataxia (FRDA).
    Type: Application
    Filed: September 23, 2020
    Publication date: November 3, 2022
    Inventors: Serena Lunardi, Adam Walter Scheidegger, Jesse Jerome Smith, Jeremiah Dale Farelli, Jodi Michelle Kennedy
  • COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN B (APOB) GENE EXPRESSION
    Publication number: 20220288237
    Abstract: The present invention provides agents and compositions for modulating expression (e.g., enhanced or reduced expression) of an apolipoprotein B (APOB) gene by targeting an APOB expression control region and methods of use thereof for treating an APOB associated disorder, e.g., hypercholesterolemia.
    Type: Application
    Filed: March 22, 2022
    Publication date: September 15, 2022
    Applicant: Omega Therapeutics, Inc.
    Inventors: Vishwesh Ashok Patil, Jeremiah D. Farelli, Rahul Karnik, Jesse Jerome Smith, Can Sarisozen, Adam Walter Scheidegger, Barbara Bennett